Mirum Pharmaceuticals is trading at $82.55, down 4.08%, alongside broader biotech weakness; however, no clear company-specific catalyst was identified.

  • XBI was down 2.01% during the session, offering relevant sector context but not fully accounting for the larger decline.
  • Mirum announced positive Phase 3 EXPAND results for LIVMARLI on October 12; available reporting does not establish those results as the cause of the October 13 drop.